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0022-2836 © 2010 Elsevier Ltd. Open accLangerin mediates the carbohydrate-dependent uptake of pathogens by
Langerhans cells in the first step of antigen presentation to the adaptive
immune system. Langerin binds to an unusually diverse number of
endogenous and pathogenic cell surface carbohydrates, including
mannose-containing O-specific polysaccharides derived from bacterial
lipopolysaccharides identified here by probing a microarray of bacterial
polysaccharides. Crystal structures of the carbohydrate-recognition
domain from human langerin bound to a series of oligomannose
compounds, the blood group B antigen, and a fragment of β-glucan
reveal binding to mannose, fucose, and glucose residues by Ca2+
coordination of vicinal hydroxyl groups with similar stereochemistry.
Oligomannose compounds bind through a single mannose residue, with
no other mannose residues contacting the protein directly. There is no
evidence for a second Ca2+-independent binding site. Likewise, a β-glucan
fragment, Glcβ1–3Glcβ1–3Glc, binds to langerin through the interaction of
a single glucose residue with the Ca2+ site. The fucose moiety of the blood
group B trisaccharide Galα1–3(Fucα1–2)Gal also binds to the Ca2+ site, and
selective binding to this glycan compared to other fucose-containing
oligosaccharides results from additional favorable interactions of the
nonreducing terminal galactose, as well as of the fucose residue.
Surprisingly, the equatorial 3-OH group and the axial 4-OH group of the
galactose residue in 6SO4–Galβ1–4GlcNAc also coordinate Ca
2+, a
heretofore unobserved mode of galactose binding in a C-type
carbohydrate-recognition domain bearing the Glu-Pro-Asn signature
motif characteristic of mannose binding sites. Salt bridges between thet of Structural Biology, Stanford University School of Medicine, 299 Campus Drive
ail address: bill.weis@stanford.edu.
ydrate-recognition domain; Man4, Manα1–3(Manα1–6)Manα1–6Man; Man5,
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ess under CC BY license.
1028 Recognition of Pathogen and Mammalian Glycans by Langerinsulfate group and two lysine residues appear to compensate for the
nonoptimal binding of galactose at this site.© 2010 Elsevier Ltd. Open access under CC BY license.IntroductionLangerhans cells found in the epidermis of the skin
and in the epithelium of mucosal tissues take up and
process antigens from invading pathogens for
presentation to T cells and thus have a critical role in
the adaptive immune response. Langerhans cells are
characterized by the presence of langerin (CD207), a
C-type lectin that can act as a pathogen receptor by
binding to surface glycoconjugates of microorgan-
isms. Langerin binds to fungi, including Malassezia
furfur and a number of Candida and Saccharomyces
species;1,2 to mycobacteria, including Mycobacterium
leprae;3 and to viruses such as human immunodefi-
ciency virus and herpes simplex virus 2.4,5 Langerin
protects against human immunodeficiency virus
infection by binding and internalizing the virus to
Birbeck granules for degradation.4,5
Langerin has an extracellular region that contains
(1) a C-type carbohydrate-recognition domain
(CRD) that binds sugars and (2) a neck region that
mediates the formation of trimers.6 Langerin recog-
nizes pathogens by binding to high-mannose
structures on viral envelope glycoproteins and to
mannan and β-glucan structures on fungal cell
walls.1,2,5,7 Glycan array analysis has shown that
langerin also binds to oligosaccharides bearing the
blood group B antigen Galα1–3(Fucα1–2)Gal and to
6-sulfated galactosides and high-mannose N-linked
oligosaccharides.2,7,8 As in other C-type lectins, the
CRDof langerin contains a conservedCa2+ binding site
that binds to carbohydrates.9 The Ca2+ forms direct
coordination bonds with vicinal hydroxyl groups on
the sugars, which also form hydrogen bonds with
amino acid side chains that are also Ca2+ ligands.10
C-type lectins broadly bind either to ligands
containing a pair of vicinal equatorial hydroxyl
groups in the same stereochemistry as the 3-OH and
4-OH groups of D-mannose or to sugars bearing
vicinal hydroxyl groups equivalent to the equatorial
3-OHgroup and the axial 4-OHgroup of D-galactose.
C-type CRDs recognizing mannose-type ligands,
including D-mannose, D-GlcNAc, D-glucose, and
L-fucose, have a signature sequence motif Glu-
Pro-Asn (EPN) on one side of the conserved Ca2+
site, whereas the equivalent residues in CRDs that
bind to galactose-type ligands have a signature
sequence motif Gln-Pro-Asp (QPD).11 Although
langerin binding to many of the ligands identified
to date is consistent with the presence of the EPN
signature motif, there are important aspects of
ligand binding specificity that remain to beexplained structurally, including selectivity for
a specific subset of ligands containing mannose,
fucose, or glucose. In addition, recognition of
6-sulfated galactosides is unexpected because of
the presence of the EPN motif.
Here we report the identification of additional
glycan ligands for langerin through screening of a
microarray of bacterial lipopolysaccharides and
high-resolution crystal structures of the langerin
CRD bound to carbohydrates representing a spec-
trum of ligands. The structures explain how langerin
can bind to such a diverse set of ligands, as well as
why some glycans are not recognized by this
protein.Results and Discussion
Novel mannose-containing ligands for langerin
A previous glycan array analysis has revealed
three classes of high-affinity ligands for langerin:
high-mannose N-linked oligosaccharides, the
fucose-containing blood group B trisaccharide, and
glycans terminating in sulfated galactose residues.7
Studies on binding to fungi and glycans derived
from them have identified both mannans and
β-glucans as ligands.1 Given this broad and struc-
turally diverse spectrum of ligands, the possibility
that there are other classes of ligands was investi-
gated using newly developedmicroarray technology
to screen a selection of glycans derived frombacterial
lipopolysaccharides (R.M., N.R., O. Berger, Y.A.K.,
and J. C. Paulson, in preparation). From a panel of 48
test ligands, two of the polysaccharides give clear
and consistent positive signals (Fig. 1). In both of
these cases, there are Manα1–2Man units in the
backbone repeat units of the polysaccharides, both
derivatized at the 6-position on the nonreducing
side. No other monosaccharide residues in these two
polysaccharides would have adjacent free hydroxyl
groups available, which would be required for
ligation to the Ca2+-centered binding site in the
langerin CRD. In addition, none of the other
polysaccharides on the array contains the Manα1–
2Man unit, suggesting that internal Manα1–2Man
disaccharides within an oligosaccharide polymer are
specific targets for langerin binding. These results
indicate that potential mannose-containing ligands
for langerin include bacterial surface polysacchar-
ides, as well as mannan-type structures on yeasts
and high-mannose oligosaccharides on viruses.
Fig. 1. Binding of langerin to bacterial polysaccharide microarray. Each O-specific polysaccharide+core released from
a bacterial lipopolysaccharide was printed in 10 versions. The first five versions were printed directly without
modification, and the second five versions were derivatized with a disubstituted oxamine linker prior to printing. Each
version was printed at 0.03 mg/mL, 0.06 mg/mL, 0.125mg/mL, 0.25 mg/mL, and 0.5 mg/mL. The data shown represent
the averages of six replicate spots for each version. A complete list of the bacterial sources of the lipopolysaccharides and
their full O-specific polysaccharide core structures is provided in Supplementary Table 1.
1029Recognition of Pathogen and Mammalian Glycans by LangerinBinding to high-mannose oligosaccharides
In order to investigate the potential modes of
binding of langerin to both eukaryotic and
prokaryotic mannose-containing sugars, we de-
termined the crystal structures for the monomeric
full-length langerin CRD bound to various
mannose-containing oligosaccharides. The crystals
used for these complexes and for all complexes
described in this article contain four copies of the
CRD in the asymmetric unit, referred to as copies
A, B, C, and D. In the first set of experiments,
binding to both eukaryotic and prokaryotic
mannose-containing oligosaccharides was investi-
gated. The first two oligosaccharides investigated
represent substructures of the eukaryotic mannose-
containing ligands: Manα1–3(Manα1–6)Manα1–
6Man (Man4) and Manα1–3(Manα1–6)Manα1–6
(Manα1–3)Man (Man5) (Fig. 2a). For both ligand
complexes, electron density was observed in the
conserved Ca2+ site in each of the four crystallo-
graphically independent copies of the CRD and was
fitted with a mannose (Fig. 2b and c). In each copy,
mannose binds with the 3-OH group interacting
with the Ca2+ ligands Glu293 and Asn307, while
the 4-OH group interacts with Glu285 and Asn287,
which are part of the EPN motif (Fig. 2d). In this
orientation, the axial 2-OH group forms a hydro-
gen bond with Lys299 (Fig. 2e).In all of the Man4 complexes, as well as in most of
the copies of the Man5 complex, only a single-
mannose residue is visible, and it cannot be
determined whether this corresponds to a particular
mannose residue present in these ligands. However,
in one copy of the CRD–Man5 complex, there is
additional electron density that is best interpreted as
an α1–3-linked mannose (Fig. 2c). Moreover, there is
weak density emerging from the anomeric oxygen
of this second sugar. These observations indicate
that the mannose residue in the primary binding site
corresponds to the outer α1–3-linked mannose
residue at the nonreducing end of the Man5
oligosaccharide, consistent with the suggestion
that langerin can bind to mannose residues at the
nonreducing termini of branched structures. At least
some of the enhanced binding seen for larger
oligosaccharides on the glycan array such as
Man5, compared to a simple branched Man3
structure, may reflect the presence of multiple
terminal residues, each of which can bind in the
primary binding site.7
Insight into the mechanism of the binding of
langerin to glycans containing Manα1–2Man
groups, found at the termini of larger branched
high-mannose eukaryotic glycans and at internal
positions in the O-specific polysaccharide chains of
bacterial lipopolysaccharides, was obtained from the
crystal structure of the CRD complexed with a
Fig. 2 (legend on next page)
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for both sugars in the disaccharide is seen in two
copies of the CRD, whereas only a single-mannose
residue is observed in the other two. The disaccha-
ride adopts the preferred conformation seen in other
crystal structures.12,13 Unlike in the Man4 and Man5
structures, two orientations for the mannose bound
in the Ca2+ site are observed, each at approximately
50% occupancy, in each of the four crystallograph-
ically independent copies of the Man2–CRD com-
plex (Fig. 2g and h). One orientation is the same as
that observed for the terminal mannose residue in
the Man4 and Man5 structures, in which the 3-OH
group coordinates Ca2+ and forms hydrogen bonds
with Glu293 and Asn307, the 4-OH group coordi-
nates Ca2+ and forms hydrogen bonds with Glu285
and Asn287, and the 2-OH group forms a hydrogen
bond with Lys299. When the full disaccharide is
visible in this orientation, the residue at the
nonreducing end is in the primary binding site,
and the 4-C of the mannose residue at the reducing
end packs against Ala289 (Fig. 2f and i). In the second
orientation, the sugar ring is rotated about an axis
perpendicular to the C3–C4 bond, so that the
partners of the 3-OH and 4-OH groups are reversed,
and the oxygen attached to the anomeric carbon
forms a hydrogen bond with Lys299 (Fig. 2g and h).
In this orientation, when the disaccharide is visible,
the reducing end residue is the one ligated to Ca2+,
and the second residue does not contact the protein
(Fig. 2j).
The structural data indicate that Manα1–2Man
groups found at the termini of high-mannose
N-linked glycans may bind in both orientations
observed in the crystal structure. In the first
conformation (Fig. 2i), the anomeric carbon at the
reducing end of Manα1–2Man points away from the
protein surface, so there is room to accommodate the
internal sugars to which the Manα1–2Man units are
attached, regardless of whether the linkage is α1–6,
α1–3, or α1–2 (Fig. 2a). The second orientation, in
which the reducing mannose is bound at the Ca2+Fig. 2. Structure of the CRD of langerin bound to high-man
green cartoon representation, with some selected side chains s
sphere. Carbohydrates are shown in stick representation. Oxyg
in blue. In (e), (i), and (j), oxygen atoms that would be linked to
as red spheres. (a) Diagram of an N-linked high-mannose olig
box), Man4 (red broken box), andManα1–2Man (gray broken b
the Manα1–3Man disaccharide from Man5. (c) Fo−Fc electron
visible in copy A, calculated by omitting themannose residues
the Ca2+ binding site. (f) Langerin carbohydrate-binding surfa
shown in surface representation: residues not interacting wi
(blue), and other residues interacting with the sugar (light bro
the mannose residue of Manα1–2Man at the Ca2+ binding site
of Manα1–2Man at the Ca2+ binding site in copy B, superim
Alternative binding modes for Manα1–2Man. The reducing
nonreducing Man residue of Manα1–2Man is marked ManNR.
bound to Ca2+) is shown superimposed on an Fo−Fc omit
disaccharide seen in copy C. (j) The alternative conformationsite (Fig. 2j), would also be able to accommodate
terminal Manα1-2Man linked α1–6 or α1–3 to
internal sugars with no steric clash. However, unless
the position of Lys299 is changed, the terminal
Manα1–2Man-linked α1–2 on the third branch could
not bind, and we see no evidence for an alternative
position of this lysine or electron density for
mannose corresponding to this arrangement. These
observations indicate that there may be multiple
modes of binding to the terminal disaccharide of
high-mannose N-linked glycans; however, given the
extra contacts formed by the reducing mannose in
Fig. 2i, it seems likely that this orientation is the
preferred mode of binding to Manα1–2Man-
containing compounds.
The structures also suggest how the internal
Manα1–2Man units found in the two strongly
interacting glycans derived from bacterial lipopoly-
saccharides (Fig. 1) may bind. In the first conforma-
tion (Fig. 2i), the chain can be readily extended from
the reducing end. At the other end of the disaccha-
ride, glycans in which the 6 position of the mannose
bound at the Ca2+ site is on the reducing side of an
α1–6-linked sugar can also be accommodated, since
the 6-OH group of this mannose points away from
the protein surface. In the alternative conformation
(Fig. 2j), the 6 position of the nonreducing mannose
is away from the protein surface, allowing elonga-
tion from this end, and an α1–3 linkage of the Ca2+-
ligated mannose to GalNAc, as in polysaccharide 44,
could also be accommodated. This mode of binding
would not be possible, however, for polysaccharide
3 as the α1–2 linkages formed by the first two
mannose residues may be sterically inaccessible, as
noted above for high-mannose N-linked glycans,
and the 4-OH group of the third mannose is linked
to another sugar and therefore cannot bind to Ca2+.
Thus, as in the case of the high-mannose structures,
the binding mode represented in Fig. 2i would seem
to be favored over that of Fig. 2j due to the more
facile accommodation of various linkages and the
extra contacts formed with the protein.nose carbohydrates. In all panels, the protein is shown in
hown in stick representation. Ca2+ is shown as an orange
en atoms are shown in red, and nitrogen atoms are shown
other sugars in larger N-linked oligosaccharides are shown
osaccharide showing the linkages in Man5 (green broken
oxes). (b) Overall secondary structure of langerin bound to
density (cyan) for the Manα1–3Man disaccharide that is
from themodel contoured at 2.7σ. (d and e)Man5 bound at
ce. Langerin CRD bound to Manα1–2Man. The protein is
th the carbohydrate (green), Ca2+ ligands (cyan), Lys299
wn). Ca2+ is shown in orange. (g) Two binding modes for
in copy A. (h) Two binding modes for the mannose residue
posed on an Fo−Fc omit map contoured at 3σ. (i and j)
Man residue of Manα1–2Man is marked ManR, and the
The second mannose residue (i.e., the residue not directly
map contoured at 2.5σ. (i) The first conformation of the
observed in copy B.
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interaction of langerin with mannose-containing
oligosaccharides involves significant contacts pri-
marily with a single mannose residue at the
conserved Ca2+ site and, in the binding mode
shown in Fig. 2i, an additional contact with the
second α1–2-linked mannose. There are also water-
mediated contacts, as observed in other protein
carbohydrate complexes.14 Thus, in contrast to
another dendritic cell receptor that recognizes high-
mannose oligosaccharides, DC-SIGN (dendritic-cell-
specific intercellular adhesion-molecule-3-grabbing
nonintegrin),15 langerin has only a small extended
binding site that contacts other sugar residues in
these oligosaccharides. The structural data show no
evidence for a proposed elongated site found by the
modeling of Manα1–2Manα1–2Man and Manα1–
2Manα1–3Man in the binding site.16 Given the
41.5-Å spacing between the binding sites of the
langerin trimer,7 it is also unlikely that multiple
termini from these oligosaccharides could simulta-
neously bind to multiple CRDs in a trimer. Instead,
enhanced binding of the langerin CRD to high-
mannose oligosaccharides relative to mannose may
be a statistical effect of having multiple available
mannose residues, as reported for DC-SIGN.17
Modeling indicates that, as observed in Man4
binding to DC-SIGN, an internal mannose, rather
than a nonreducing terminal mannose, could be
accommodated at the conserved Ca2+ site,16 which
would increase the number of potential binding
modes.
A second Ca2+-independent site for mannose was
reported in a structure of langerin bound to
mannose monosaccharide.9 We see no evidence for
mannose in this site in any of the 12 crystallograph-
ically independent views of langerin binding to the
Manα1–2Man, Man4, or Man5 oligosaccharides. In a
previous report, this site was present in only two of
the four copies in the asymmetric unit, and
inspection of electron density maps made from
deposited coordinates and structure factors indi-
cates that the electron density in this site was
misidentified as a sugar. Instead, it appears to be a
tryptophan residue from the C-terminal affinity
purification tag of a neighboring molecule in the
lattice, as it is also present in the unliganded
structure. The CRD construct used here contains
no affinity tags, and this density is absent. The
authors of the previous study have confirmed that
the density was indeed misidentified, and the
deposited coordinates have been updated [A.
Skerra, personal communication; Protein Data
Bank (PDB) entries 3P7G, 3P7H, and 3P7F]. Note
that this region of the protein is a flexible loop, and
there appears to be some weak electron density
corresponding to an alternative loop conformation;7
it was modeled here as such a mixture in some of the
copies in the asymmetric units.Structure of langerin bound to the blood group B
trisaccharide
The primary fucose-containing ligands for lan-
gerin identified by glycan array analysis contain
the blood group B epitope Galα1–3(Fucα1–2)Gal.
This oligosaccharide is found in several pathogenic
bacteria such as Helicobacter pylori and Escherichia
coli. In the case of E. coli strain O86, it has been
suggested that binding of galectins in the gut to
the blood group B epitope may result in pathogen
neutralization,18 but the binding of langerin to the
same epitope suggests that it may also participate
in the defense against some strains of bacteria. In
contrast to a number of other C-type CRDs,
langerin does not bind Lewisa and Lewisx trisac-
charides. In order to investigate the basis for this
binding specificity, we determined the structure of
the langerin CRD bound to the blood group B
trisaccharide.
The bound blood group B trisaccharide was found
to have the same orientation in all four CRDs in the
asymmetric unit of the cocrystals. The fucose moiety
binds to the Ca2+ site, with the equatorial 2-OH and
3-OH groups coordinating Ca2+ (Fig. 3a–c). In
addition to the four Ca2+ ligands that form
hydrogen bonds to the 2-OH and 3-OH groups of
fucose, the 4-OH group forms a hydrogen bond with
Lys299, and the ring 3-C packs against the side chain
of Ala289 (Fig. 3c and d). The central galactose
residue is positioned away from the protein, but the
nonreducing galactose residue packs against Cα of
Gly284 and the side chains of Ile282, Glu285, and
Asn287. The 4-OH group of this galactose also forms
a hydrogen bond with the backbone carbonyl
oxygen of Pro283, and the 6-OH group is hydrogen
bonded to the side-chain amide group of Asn287
(Fig. 3e and f). Since Asn287 also donates a
hydrogen bond to the bound fucose, this residue
bridges the fucose and galactose moieties (Fig. 3c
and e). The 2-OH group of the nonreducing terminal
galactose points away from the protein surface,
explaining why the blood group A trisaccharide
GalNAcα1–3(Fucα1–2)Gal can bind to langerin,
albeit more weakly than the blood group B
trisaccharide.
There are multiple instances of fucose-containing
ligands that bind to C-type CRDs with the EPN
signature, but two very different orientations of
fucose residues in the primary binding site have been
observed. Fucose monosaccharide is bound to the
relatively open binding site in the CRD of rat serum
mannose-binding protein with the 2-OH and 3-OH
groups coordinated to Ca2+; thus, in the absence of
other contacts with the protein, this configuration
appears to be energetically favored.20,21 However,
in oligosaccharides, the 3-OH and 4-OH groups of
a fucose residue in the primary binding site are
often coordinated to Ca2+. For example, the latter
Fig. 3. Structure of the CRD of langerin bound to the blood group B trisaccharide. The color scheme is the same as that
described in Fig. 2. (a) Overall structure of protomer A bound to the trisaccharide. (b) Top: Diagram of the blood group B
trisaccharide showing linkages between the sugars. Bottom: Fo−Fc electron density (3.0σ; cyan), calculated by omitting
the trisaccharide model. (c and d) Fucose moiety bound at the Ca2+ binding site. (e) Terminal galactose moiety of the blood
group B trisaccharide in the extended binding site. (f) Langerin carbohydrate-binding surface. Langerin CRD bound to the
blood group B trisaccharide. The protein is shown in surface representation: residues not interacting with the
carbohydrate (green), Ca2+ ligands (cyan), Lys299 (blue), and other residues interacting with the sugar (light brown). Ca2+
is shown in orange. (g) Model for Lewisx binding through hydroxyl groups 2 and 3 of fucose. The fucose moiety of Lewisx
bound to DC-SIGN19 (PDB entry 1SL5) was superimposed on the fucose of the blood group B trisaccharide. Carbon atoms
in the Lewisx trisaccharide are shown in cyan. (h) Model for Lewisx binding through hydroxyl groups 3 and 4 of fucose.
The CRD of DC-SIGN bound to lacto-N-fucopentaose III (PDB entry 1SL5) was superimposed on the CRD of langerin. For
simplicity, only the Lewisx moiety of lacto-N-fucopentaose III is shown (light blue). (i) Comparison of the two potential
modes for fucose binding to the Ca2+ site. Fucose from the structure of langerin bound to the blood group B trisaccharide
is shown in yellow, and fucose from the superposition described in (g) is shown in light blue.
1033Recognition of Pathogen and Mammalian Glycans by Langerinconfiguration is seen for ligands that contain the
Lewisx group Galβ1–4(Fucα1–3)GlcNAc bound to
selectins22 or to DC-SIGN.19 Binding of the fucose
residues in this orientation results in favorable
contacts with both fucose and galactose residues,
while the different configuration of the blood
group B trisaccharide and the different arrange-
ment of residues in the region around the primary
binding site in langerin result in a different set offavorable contacts when the fucose residue in the
blood group B trisaccharide is coordinated through
the 2-OH and 3-OH groups.
Unlike DC-SIGN, langerin does not bind the
Lewisx and Lewisa (Galβ1–3(Fucα1–4)GlcNAc)
trisaccharides.1,5 The Lewisx trisaccharide has a
well-defined conformation, which enables modeling
to probe why it cannot bind to langerin. Lewisx
binding to the langerin CRD was modeled in two
1034 Recognition of Pathogen and Mammalian Glycans by Langerinpossible ways. In one case, the fucose of Lewisx was
superimposed onto the fucose residue of the blood
group B trisaccharide, with the 2-OH and 3-OH
groups coordinating Ca2+ (Fig. 3g). In this case, the
central GlcNAc of Lewisx would be positioned away
from the protein similarly to the central galactose
residue of the blood group B trisaccharide. However,
because the fucose is linked to the 3 position of
GlcNAc rather than to the 2 position, the GlcNAc is
rotated about 60° with respect to the reducing
galactose residue in the blood group B trisaccharide.
This change places the β-linked galactose residue in
Lewisx on the opposite side of the central sugar
relative to the position of galactose in the blood
group B trisaccharide. It would thus clash with
Ala289, which is part of a rigid loop in langerin and
other C-type CRDs (Fig. 3g). In the second model,
the CRDs of DC-SIGN and langerin were super-
imposed so that the 3-OH and 4-OH groups of the
fucose residue coordinate Ca2+ (Fig. 3h and i). In
this case, there are no clashes with the CRD, but
key residues that stabilize DC-SIGN binding to
Lewisx are absent in langerin, since residues
Asp367, Lys368, Leu371, and Lys373 of DC-SIGN
are replaced by Ala309, Pro310, Lys313, and
Phe315 in langerin (Fig. 3h).
β-Glucan binding
Langerin binding to mannans and β-glucans that
are components of fungal cell walls has been
documented.1 The structures described above sug-
gest a mechanism for the binding of Manα1–2Man
units in the main chains or branches of mannans.
The interaction with β-glucans was probed using a
complex of Glcβ1–3Glcβ1–3Glc (laminaritriose)
bound to the langerin CRD. In one copy of theCRD, a single-glucose residue representing the
nonreducing end of the trisaccharide is visible,
with its 3-OH and 4-OH groups coordinating Ca2+
and forming hydrogen bonds with Ca2+ ligands, as
previously seen for the reducing glucose residue in
maltose (Glcβ1–4Glc)9 (Fig. 4a and b). However, no
additional interactions with the other two sugar
residues are observed. In β1–6-linked glucans, there
would be multiple residues that could bind in this
mode, although only the nonreducing termini of β1–
3 glucans would be able to bind. In another copy, a
Glcβ1–3Glc disaccharide is visible, with the reduc-
ing end of the trisaccharide binding to Ca2+ through
the equatorial 1-OH and 2-OH groups (Fig. 4c and
d), indicating that langerin could bind to either end
of a free glucan. The observed β1–3 linkage falls in
the broad conformational minimum observed in
databases of glycan structures.13
Binding to glycans bearing 6-sulfated galactose
In contrast to the other ligands identified by
screening on synthetic and pathogen glycan arrays,
oligosaccharides bearing terminal 6SO4–Gal resi-
dues are not found on pathogen surfaces. However,
binding to such structures has been suggested to
mediate interaction with endogenous sulfated
ligands such as keratan sulfate, which contains the
6SO4–Galβ1–4GlcNAc repeating unit.
2 Langerin is
unique among receptors with C-type CRDs because
of its ability to bind both mannose/fucose-type
ligands and a galactose-based ligand. The structural
basis for this unusual binding was investigated by
determining the structure of the CRD with the
bound 6SO4–Galβ1–4GlcNAc ligand.
Electron density in all four copies of the CRD
clearly shows both 6SO4–Gal and GlcNAc residuesFig. 4. Structure of the CRD of
langerin bound to laminaritriose.
The color scheme is the same as that
described in Fig. 2. (a) Nonreducing
glucose residue bound to monomer
C. (b) Fo−Fc electron density map
(green), calculated by omitting the
sugars (3.0σ) showing laminari-
triose monomer C. (c) The reducing
and central glucose residues visible
in monomer B. (d) Fo−Fc electron
density omit maps of langerin CRD
bound to laminaritriose monomer
B. Map contours at 3.0σ and 2.2σ
are shown in blue and green,
respectively.
Fig. 5. Structure of the CRD of langerin bound to 6SO4–Gal–GlcNAc. The color scheme is the same as that described in
Fig. 2. (a) Langerin carbohydrate-binding surface. Langerin CRD bound to 6SO4–Galβ1–4GlcNAc. The protein is shown
in surface representation: residues not interacting with the carbohydrate (green), Ca2+ ligands (cyan), Lys299 and Lys313
(blue), and other residues interacting with the sugar (light brown). Ca2+ is with in orange. (b) Top: Chemical structure of
6SO4–Galβ1–4GlcNAc. Bottom: Fo−Fc omit map (3.0σ) of 6SO4–Galβ1–4GlcNAc (cyan). (c) 6SO4–Gal at the Ca2+ binding
site. (d) Comparison of mannose binding (cyan) and 6SO4–Gal binding (yellow) at the Ca
2+ site in langerin. The CRDs
observed in the Man4 and 6SO4–Galβ1–4GlcNAc complexes were superimposed in order to position the mannose residue
on the 6SO4–Galβ1–4GlcNAc structure. (e) Side view of the Ca
2+ site bound to 6SO4–Galβ1–4GlcNAc. (f) The position of
the sulfate moiety of 6SO4–Galβ1–4GlcNAc in the binding site.
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poorly to galactose compared to mannose and
fucose,6 the galactose residue is bound in the Ca2+
site (Fig. 5a and c). The Ca2+ ligands Glu293 and
Asn307 form hydrogen bonds with the axial 4-OH
group of 6SO4–Gal, and Glu285 and Asn287
coordinate Ca2+ and form hydrogen bonds with
the equatorial 3-OH group of 6SO4–Gal. The
equatorial/axial geometry of these two hydroxyl
groups tilts the galactose pyranose ring relative to
mannose (Fig. 5d and e) so that it packs against
Ala289. The SO4 group forms salt bridges with
Lys299 and Lys313, consistent with previously
published results showing that Lys299Ala or
Lys313Ala mutations abolish binding to the
disaccharide2 (Fig. 5f). The charge–charge interac-
tions between these lysine residues and the sulfate
group must compensate for the presumably nonop-
timal Ca2+ ligation of galactose at a site with an EPN
signature because langerin does not bind to non-
sulfated galactosides.2,6
Previous studies showed binding of langerin to
Lewisx-type carbohydrates containing 6-sulfated
galactose.2,8 Since langerin does not bind Lewisx,
high-affinity binding to 6SO4–Lewis
x likely arisesfrom interactions of the sulfated galactose similar
to those described here for 6SO4–Galβ1–4GlcNAc.
The structure also explains why langerin does not
bind to 3-sulfated galactose groups,2,7,8 since the
3-OH group is involved in Ca2+ coordination and
hydrogen-bonding interactions in the conserved site.Conclusion
Langerin combines the features of several other
C-type lectins. The organization of the trimer
suggests that the multiple binding sites are widely
spaced and probably rigidly positioned in a manner
reminiscent of mannose-binding protein.7 However,
although the binding site in each CRD is relatively
open as in mannose-binding proteins, the glycan
array results reported here and elsewhere indicate
that langerin shows preferential binding to specific
ligands rather than broad specificity resulting from
the binding of just terminal sugar residues, as seen for
mannose-binding protein. The structures of the
langerin–ligand complexes reveal that this preferen-
tial binding results from a small number of favorable
contacts with portions of selected oligosaccharide
Table 1. Crystallographic data statistics
Data
Langerin
CRD+blood
group B trisaccharide
Langerin
CRD+Man5
Langerin
CRD+Man4
Langerin
CRD+Manα1–2Man
Langerin CRD+
6SO4–Gal–GlcNAc
Langerin CRD+
laminaritriose
Space group P42 P42 P42 P42 P42 P42
Unit cell parameters
a, b, c (Å)
79.86, 79.86,
90.17
79.34, 79.34,
89.67
79.31, 79.31,
89.58
79.78, 79.78,
90.47
79.81, 79.81,
90.74
80.11, 80.11,
90.72
Resolution
(last shell) (Å)
39.93–1.60 (1.69–1.60) 44.83–1.80
(1.90–1.80)
44.79–1.70
(1.79–1.70)
39.89–1.75
(1.84–1.75)
47.92–1.80
(1.90–1.80)
36.64–1.60
(1.69–1.60)
Rsym (last shell)
a 5.3 (24.0) 6.9 (37.4) 6.3 (40) 6.3 (24.8) 6.5 (28.1) 5.3 (28.1)
Mean ((I)/σ(I))
(last shell)
13.9 (4.8) 18.2 (5.4) 20.3 (4.9) 20.0 (7.3) 18.6 (6.5) 22.0 (6.4)
% Completeness
(last shell)
100 (100) 100 (99.9) 100 (100) 100 (100) 100 (100) 99.9 (100)
Number of unique
reflections
74,505 51,453 60,951 57,096 52,682 75,402
Average multiplicity
(last shell)
3.8 (3.8) 7.7 (7.6) 7.6 (7.6) 7.6 (7.6) 7.7 (7.6) 7.6 (7.5)
a Rsym=∑h∑i(|Ii(h)|−|〈I(h)〉|)/∑h∑iIi(h), where Ii(h) is the observed intensity, and 〈I(h)〉 is the mean intensity obtained frommultiple
measurements.
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primary binding site (Figs. 2f, 3f, and 5a). In this
respect, the binding site has some of the features of
the binding site in DC-SIGN, although secondary
contacts are less extensive. The structural analysis
also shows that the primary binding site is able to
bind both mannose-type and galactose-type ligands,
but the absolute requirement for the sulfation of the
galactose residue is explained by direct interactions
with a positively charged region of the extended
binding site. The subtlety of the secondary interac-
tions that determine the binding selectivity of
langerin illustrates the difficulty of predicting bind-
ing specificity from a comparative analysis of even
closely related CRDs.†Available from www.functionalglycomics.org/static/
consortium/resources/timelined2p.shtml
‡www.functionalglycomics.orgMaterials and Methods
Carbohydrates
6SO4–Galβ1–4GlcNAc was purchased from Carbo-
synth, and Manα1–2Man was purchased from Sigma.
All other sugars were purchased from V-labs, Inc.
Protein production and labeling
The full-length CRD of human langerin was expressed
in E. coli and purified by affinity chromatography on
mannose Sepharose, as described previously.6 The CRD
construct used contains residues 193–328 of human
langerin similar to the one used in a previous crystallo-
graphic study,9 but it does not have any appended tag for
purification. A stable trimeric fragment of the extracellular
domain containing part of the neck region, as well as the
CRD (designated truncated langerin), was also produced
in E. coli and labelled with fluorescein, as described
previously.7Glycan microarray analysis
Details of the bacterial polysaccharide microarray
preparation will be described elsewhere (R.M., N.R., O.
Berger, Y.A.K., and J. C. Paulson, in preparation)†. Lipid A
was removed by mild acid hydrolysis, and the remaining
O-specific polysaccharide+core structures were either
covalently attached (through amino groups in the inner
core) directly to N-hydroxysuccinimide-activated glass
slides or derivatized at the reducing Kdo residue with
2-aminoethyl-(N-methyl)-hydroxylamine before spotting.
The microarray was screened with fluorescein-labelled
truncated langerin following the standard procedure of
Core H of the Consortium for Functional Glycomics
(protocol cfgPTC_243‡).
Crystallization and data collection
Crystals of langerin CRD–carbohydrate complexes were
obtained by hanging-drop vapor diffusion, using a
mixture of 1.5 μL of protein–carbohydrate complex and
0.75 μL of reservoir solution in a drop. All crystals were
grown at 22 °C. Crystals of langerin CRD bound to the
blood group B trisaccharide and mannose-containing
oligosaccharides were grown from a protein solution
comprising 5 mg/mL langerin CRD, 2.5 mM CaCl2,
10 mM Tris–Cl (pH 8.0), and 25 mMNaCl. Carbohydrates
were added to the protein solution prior to crystallization
to a final concentration of 5 mM blood group B
trisaccharide, 10 mM Man5 and Man4 oligosaccharides,
or 30 mM Manα1–2Man. The complexes with 6SO4–
Galβ1–4GlcNAc and laminaritriose were crystallized from
a solution containing 2.5 mg/mL langerin CRD, 1.25 mM
CaCl2, 5 mM Tris (pH 8.0), and 12.5 mMNaCl, with 6SO4–
1037Recognition of Pathogen and Mammalian Glycans by LangerinGalβ1–4GlcNAc or laminaritriose added to final concen-
trations of 7.5 mM and 15 mM, respectively. The reservoir
solution contained 0.1 M Hepes (pH 7.0), 0.25 M MgCl2,
and 20%, 25%, or 31% polyethylene glycol (PEG) 4000 for
crystals containing blood group B and Man5 and Man4
oligosaccharides, respectively. For the crystallization of
langerin CRD bound to Manα1–2Man, 6SO4–Galβ1–
4GlcNAc, or laminaritriose, the reservoir solution
contained 0.1 M Hepes (pH 7.0), 0.1 M MgCl2, and 25%,
25%, or 20% PEG 4000.
Crystals of langerin CRD complexed with Man5
oligosaccharide transferred to a solution containing all
components of the crystallization drop apart from the
protein, but with a PEG 4000 concentration of 34%,
were frozen in liquid nitrogen for data collection.
Other crystals were transferred to perfluoropolyether
(PFO-XR75; Lancaster Synthesis) before being frozen in
liquid nitrogen for data collection. Diffraction data
were measured at 100 K on beamline 11-1 of the
Stanford Synchrotron Radiation Lightsource. Data were
processed with MOSFLM and SCALA,23 and are
summarized in Table 1.
Structure determination
All crystals belonged to space group P42 with unit cell
parameters very similar to those published for the
langerin CRD,9 allowing structure solution directly byTable 2. Crystallographic refinement statistics
Data
Langerin CRD+
blood group B
trisaccharide
Langerin
CRD+Man5
Lange
CRD+ M
Residues in the final model
Copy A: protein residues 198–325 198–325 198–3
Copy A: sugars 1 Trisaccharide 2 Man 1 Ma
Copy B: protein residues 198–325 198–325 198–3
Copy B: sugars 1 Trisaccharide 1 Man 1 Ma
Copy C: protein residues 197–325 196–325 196–3
Copy C: sugars 1 Fuc 1 Man 1 Ma
Copy D: protein residues 197–325 197–324 197–3
Copy D: sugars 1 Fuc 1 Man 1 Ma
Water molecules 819 526 570
Number of reflections used
for refinement
70,325 48,636 57,65
Reflections marked for Rfree 3742 2619 309
Rfree
a 21.9 22.0 21.2
Rcryst
a 17.9 17.4 17.3
Average B-factor 23.5 26.7 24.6
Average B-factor for
carbohydrate
35.8 40.2 32.8
RMSD of bond length (Å) 0.007 0.007 0.00
RMSD of bond angle (°) 1.1 1.1 1.1
Ramachandran plot
Preferred/allowed/
outliers (%)b
96.0/4.0/0 96.0/4.0/0.0 95.7/4.3
a R and Rfree=∑‖Fo|−|Fc‖/∑|Fo|, where |Fo| is the observed str
amplitude for the working and test sets, respectively.
b As defined in Coot.25rigid-body refinement. The crystallographic asymmetric
unit contains four copies of the CRD. Because of the
ambiguity in assigning the direction of the c-axis in this
space group, the indexing of all data sets was tested for
consistency to a reference set (PDB entry 3BC79), which
facilitated comparisons of these isomorphous structures.
Specifically, each set was scaled to the reference using
nonreindexed data andwith the data reindexed as (k, h,− l).
The indexing that gave better scaling statistics was chosen.
The same reflections were marked for the test set in each
case. The model from PDB entry 3BC7, without mannose
or water molecules, was used as starting model for the
refinement of the complex of langerinwith the blood group
B trisaccharide. A partially refined model of this complex,
excluding all waters and sugars from the model, was used
as starting model for the refinement of the other data sets.
Model building and refinement were performed with
Coot and PHENIX.24,25 Refinement included individual
positional and isotropic temperature factor refinement
for all atoms, except that Ca2+ was refined with an
anisotropic temperature factor model. Refinement statis-
tics, including the residues modeled in each case, are
shown in Table 2.
PDB accession codes
Atomic coordinates and structure factors have been
deposited in the PDB, Research Collaboratory forrin
an4
Langerin
CRD+Manα1–2Man
Langerin
CRD+6SO4–
Gal–GlcNAc
Langerin CRD+
laminaritriose
25 198–325 198–325 198–325
n 1 Man 1 6SO4–Gal–
GlcNAc
1 Glc
25 198–325 198–325 197–325
n 2 Man 1 6SO4–Gal–
GlcNAc
2 Glc
25 197–325 197–325 196–325
n 2 Man 1 6SO4–Gal–
GlcNAc
1 Glc
24 197–325 197–325 197–324
n 1 Man 1 6SO4–Gal–
GlcNAc
2 Glc
599 479 717
7 54,038 49,700 70,704
9 2897 2670 3753
21.6 22.3 21.4
17.3 17.8 17.9
23.1 26.2 23.7
29.9 46.2 39.0
7 0.007 0.007 0.007
1.1 1.1 1.1
/0.0 95.6/4.4/0.0 95.4/4.6/0.0 95.8/4.2/0.0
ucture factor amplitude and |Fc| is the calculated structure factor
1038 Recognition of Pathogen and Mammalian Glycans by LangerinStructural Bioinformatics§, Rutgers University (New
Brunswick, NJ), with accession codes 3P5D (Man5
complex), 3P5E (Man4 complex), 3P5F (Man2 complex),
3P5G (blood group B complex), 3P5H (laminaritriose
complex), and 3P5I (6SO4–Galβ1–4GlcNAc complex).
Supplementary materials related to this article can be
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